Agios Pharmaceutical (AGIO) 36.74 $AGIO How The
Post# of 273258
Posted On: 09/02/2016 3:04:39 AM
Agios Pharmaceutical (AGIO) 36.74 $AGIO
How These Biotech Stocks are Faring? -- Progenics Pharma, Peregrine Pharma, Agios Pharma, and Cara Therapeutics
PR Newswire - Fri Aug 26, 6:50AM CDT
Stock-Callers.com has initiated research reports on the following Biotech companies: Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), and Cara Therapeutics Inc. (NASDAQ: CARA). On Wednesday, August 24, 2016, the iShares NASDAQ Biotechnology ETF (IBB) plummeted 3% after Democratic presidential candidate Hillary Clinton tweeted about the price hikes on EpiPens. Register now and get full and free access to our downloadable research reports on these stocks at:
CARA: 5.38 (-0.04), PGNX: 6.14 (-0.14), PPHM: 0.36 (unch), AGIO: 36.74 (-0.10)
Agios Appoints Andrew Hirsch as Chief Financial Officer
GlobeNewswire - Tue Aug 16, 6:30AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that Andrew Hirsch is joining the company as chief financial officer, effective September 19, 2016. Mr. Hirsch has more than 20 years of experience in a range of strategic and operating roles in the biotechnology sector, most recently having served as president and chief executive officer of BIND Therapeutics.
AGIO: 36.74 (-0.10), BIND: 0.78 (-0.09)
Agios (AGIO) Q2 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 10:10AM CDT
Agios Pharmaceuticals (AGIO) reported a wider-than-expected second-quarter 2016 loss of $1.47 per share.
GERN: 2.73 (+0.04), AGIO: 36.74 (-0.10), ANIK: 47.94 (+0.70), CELG: 106.37 (-0.37)
Agios to Present at Canaccord Genuity 36th Annual Growth Conference Wednesday, August 10, 2016
GlobeNewswire - Fri Aug 05, 6:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company is scheduled to present at the Canaccord Genuity 36th Annual Growth Conference in Boston on Wednesday, August 10, 2016 at 8:00 a.m. ET.
AGIO: 36.74 (-0.10)
Agios (AGIO) Reports Wider-than-Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 7:50AM CDT
Agios (AGIO) posted wider-than-expected loss in the second quarter of 2016.
AGIO: 36.74 (-0.10)
Agios Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 6:01AM CDT
- Data from PKR Activators at EHA Demonstrated Proof-of-Concept for AG-348 and Proof-of-Mechanism for AG-519; Program Moving Toward Pivotal Development in PK Deficiency with Molecule Selection by Year-End 2016 -
AGIO: 36.74 (-0.10)
Medical Product Stock Earnings on Aug 4: NXTM, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:56AM CDT
Here, we take a look at four Medical product stocks set to report their quarterly figures on Aug 4.
NXTM: 22.86 (unch), AGIO: 36.74 (-0.10), ATRC: 15.50 (+0.11), HRC: 59.25 (-0.06)
Will Agios (AGIO) Disappoint Estimates in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 10:23AM CDT
Agios Pharmaceuticals (AGIO), which is set to report second-quarter 2016 results on Aug 4, had posted a positive surprise of 11.59% last quarter.
ICPT: 146.82 (-1.49), AGIO: 36.74 (-0.10), EXEL: 11.35 (+0.20), CELG: 106.37 (-0.37)
Agios to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016
GlobeNewswire - Thu Jul 28, 3:01PM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2016 at 8:30 a.m. ET to report its second quarter 2016 financial results and discuss recent clinical development and corporate activities.
AGIO: 36.74 (-0.10)
Agios Reports Favorable Phase II PK Deficiency Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:56AM CDT
Agios Pharmaceuticals (AGIO) reported encouraging initial data from an ongoing phase II DRIVE-PK study on pyruvate kinase deficiency candidate AG-348.
PFE: 34.68 (-0.12), RTRX: 16.35 (+0.33), AGIO: 36.74 (-0.10), BMY: 56.76 (-0.63)
Agios Reports Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers
GlobeNewswire - Thu Jun 09, 8:21AM CDT
- Data Demonstrate Favorable Safety Profile with up to 14 Days of Daily Dosing -
AGIO: 36.74 (-0.10)
What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.45 (+0.01), INSY: 14.36 (+0.09), AGIO: 36.74 (-0.10), GNCA: 5.28 (-0.08)
Agios to Host Conference Call from the 21st Congress of the European Hematology Association
GlobeNewswire - Wed Jun 01, 6:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Saturday, June 11, 2016 at 9:30 a.m. ET to discuss clinical and preclinical data presented at the 21st Congress of the European Hematology Association (EHA) taking place June 9-12, 2016 in Copenhagen.
AGIO: 36.74 (-0.10)
Agios to Present Clinical and Preclinical Data from PKR Activators AG-348 and AG-519 at the 21st Congress of the European Hematology Association
GlobeNewswire - Thu May 19, 6:01AM CDT
Initial Data to be Presented from AG-348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study
AGIO: 36.74 (-0.10)
Agios Strikes Metabolic Immuno-Oncology Deal with Celgene
Zacks Equity Research - Zacks Investment Research - Wed May 18, 10:00AM CDT
Agios Pharmaceuticals (AGIO) inked a metabolic immuno-oncology agreement with Celgene; Agios gained global rights to AG-120 and updated 2016 view.
ANIP: 61.42 (+1.68), RTRX: 16.35 (+0.33), AGIO: 36.74 (-0.10), CELG: 106.37 (-0.37)
Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement
GlobeNewswire - Tue May 17, 3:01PM CDT
- New Collaboration Builds on Agios Research Platform and Leverages Celgene Capabilities; Agios to Receive $200 Million Upfront Payment -
AGIO: 36.74 (-0.10), CELG: 106.37 (-0.37), CELGZ: 1.13 (-0.03)
Agios (AGIO) Q1 Loss Lower than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:51AM CDT
Agios Pharmaceuticals (AGIO) reported a first-quarter 2016 loss of 61 cents per share, much narrower than the Zacks Consensus Estimate of a loss of 69 cents.
ANIP: 61.42 (+1.68), RTRX: 16.35 (+0.33), AGIO: 36.74 (-0.10), CELG: 106.37 (-0.37)
Agios Pharmaceuticals reports 1Q loss
Automated Insights - Thu May 05, 2:45PM CDT
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Thursday reported a loss of $23.2 million in its first quarter.
AGIO: 36.74 (-0.10)
Agios Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 6:01AM CDT
Five Abstracts Accepted for Presentation at EHA in June, Including First Data from AG -348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study
AGIO: 36.74 (-0.10)
Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 42.30 (+0.28), BIIB: 306.03 (+0.40), CNAT: 1.86 (+0.05), AMGN: 170.13 (+0.07), RPRX: 2.00 (-0.03), JNJ: 119.08 (-0.26), GILD: 77.42 (-0.96), GWPH: 82.28 (+0.53), GERN: 2.73 (+0.04), AVEO: 0.91 (-0.02), ICPT: 146.82 (-1.49), AGIO: 36.74 (-0.10), NVS: 78.27 (-0.50)
How These Biotech Stocks are Faring? -- Progenics Pharma, Peregrine Pharma, Agios Pharma, and Cara Therapeutics
PR Newswire - Fri Aug 26, 6:50AM CDT
Stock-Callers.com has initiated research reports on the following Biotech companies: Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), and Cara Therapeutics Inc. (NASDAQ: CARA). On Wednesday, August 24, 2016, the iShares NASDAQ Biotechnology ETF (IBB) plummeted 3% after Democratic presidential candidate Hillary Clinton tweeted about the price hikes on EpiPens. Register now and get full and free access to our downloadable research reports on these stocks at:
CARA: 5.38 (-0.04), PGNX: 6.14 (-0.14), PPHM: 0.36 (unch), AGIO: 36.74 (-0.10)
Agios Appoints Andrew Hirsch as Chief Financial Officer
GlobeNewswire - Tue Aug 16, 6:30AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that Andrew Hirsch is joining the company as chief financial officer, effective September 19, 2016. Mr. Hirsch has more than 20 years of experience in a range of strategic and operating roles in the biotechnology sector, most recently having served as president and chief executive officer of BIND Therapeutics.
AGIO: 36.74 (-0.10), BIND: 0.78 (-0.09)
Agios (AGIO) Q2 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 10:10AM CDT
Agios Pharmaceuticals (AGIO) reported a wider-than-expected second-quarter 2016 loss of $1.47 per share.
GERN: 2.73 (+0.04), AGIO: 36.74 (-0.10), ANIK: 47.94 (+0.70), CELG: 106.37 (-0.37)
Agios to Present at Canaccord Genuity 36th Annual Growth Conference Wednesday, August 10, 2016
GlobeNewswire - Fri Aug 05, 6:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company is scheduled to present at the Canaccord Genuity 36th Annual Growth Conference in Boston on Wednesday, August 10, 2016 at 8:00 a.m. ET.
AGIO: 36.74 (-0.10)
Agios (AGIO) Reports Wider-than-Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 7:50AM CDT
Agios (AGIO) posted wider-than-expected loss in the second quarter of 2016.
AGIO: 36.74 (-0.10)
Agios Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 6:01AM CDT
- Data from PKR Activators at EHA Demonstrated Proof-of-Concept for AG-348 and Proof-of-Mechanism for AG-519; Program Moving Toward Pivotal Development in PK Deficiency with Molecule Selection by Year-End 2016 -
AGIO: 36.74 (-0.10)
Medical Product Stock Earnings on Aug 4: NXTM, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:56AM CDT
Here, we take a look at four Medical product stocks set to report their quarterly figures on Aug 4.
NXTM: 22.86 (unch), AGIO: 36.74 (-0.10), ATRC: 15.50 (+0.11), HRC: 59.25 (-0.06)
Will Agios (AGIO) Disappoint Estimates in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 10:23AM CDT
Agios Pharmaceuticals (AGIO), which is set to report second-quarter 2016 results on Aug 4, had posted a positive surprise of 11.59% last quarter.
ICPT: 146.82 (-1.49), AGIO: 36.74 (-0.10), EXEL: 11.35 (+0.20), CELG: 106.37 (-0.37)
Agios to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016
GlobeNewswire - Thu Jul 28, 3:01PM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2016 at 8:30 a.m. ET to report its second quarter 2016 financial results and discuss recent clinical development and corporate activities.
AGIO: 36.74 (-0.10)
Agios Reports Favorable Phase II PK Deficiency Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:56AM CDT
Agios Pharmaceuticals (AGIO) reported encouraging initial data from an ongoing phase II DRIVE-PK study on pyruvate kinase deficiency candidate AG-348.
PFE: 34.68 (-0.12), RTRX: 16.35 (+0.33), AGIO: 36.74 (-0.10), BMY: 56.76 (-0.63)
Agios Reports Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers
GlobeNewswire - Thu Jun 09, 8:21AM CDT
- Data Demonstrate Favorable Safety Profile with up to 14 Days of Daily Dosing -
AGIO: 36.74 (-0.10)
What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.45 (+0.01), INSY: 14.36 (+0.09), AGIO: 36.74 (-0.10), GNCA: 5.28 (-0.08)
Agios to Host Conference Call from the 21st Congress of the European Hematology Association
GlobeNewswire - Wed Jun 01, 6:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Saturday, June 11, 2016 at 9:30 a.m. ET to discuss clinical and preclinical data presented at the 21st Congress of the European Hematology Association (EHA) taking place June 9-12, 2016 in Copenhagen.
AGIO: 36.74 (-0.10)
Agios to Present Clinical and Preclinical Data from PKR Activators AG-348 and AG-519 at the 21st Congress of the European Hematology Association
GlobeNewswire - Thu May 19, 6:01AM CDT
Initial Data to be Presented from AG-348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study
AGIO: 36.74 (-0.10)
Agios Strikes Metabolic Immuno-Oncology Deal with Celgene
Zacks Equity Research - Zacks Investment Research - Wed May 18, 10:00AM CDT
Agios Pharmaceuticals (AGIO) inked a metabolic immuno-oncology agreement with Celgene; Agios gained global rights to AG-120 and updated 2016 view.
ANIP: 61.42 (+1.68), RTRX: 16.35 (+0.33), AGIO: 36.74 (-0.10), CELG: 106.37 (-0.37)
Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement
GlobeNewswire - Tue May 17, 3:01PM CDT
- New Collaboration Builds on Agios Research Platform and Leverages Celgene Capabilities; Agios to Receive $200 Million Upfront Payment -
AGIO: 36.74 (-0.10), CELG: 106.37 (-0.37), CELGZ: 1.13 (-0.03)
Agios (AGIO) Q1 Loss Lower than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:51AM CDT
Agios Pharmaceuticals (AGIO) reported a first-quarter 2016 loss of 61 cents per share, much narrower than the Zacks Consensus Estimate of a loss of 69 cents.
ANIP: 61.42 (+1.68), RTRX: 16.35 (+0.33), AGIO: 36.74 (-0.10), CELG: 106.37 (-0.37)
Agios Pharmaceuticals reports 1Q loss
Automated Insights - Thu May 05, 2:45PM CDT
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Thursday reported a loss of $23.2 million in its first quarter.
AGIO: 36.74 (-0.10)
Agios Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 6:01AM CDT
Five Abstracts Accepted for Presentation at EHA in June, Including First Data from AG -348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study
AGIO: 36.74 (-0.10)
Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 42.30 (+0.28), BIIB: 306.03 (+0.40), CNAT: 1.86 (+0.05), AMGN: 170.13 (+0.07), RPRX: 2.00 (-0.03), JNJ: 119.08 (-0.26), GILD: 77.42 (-0.96), GWPH: 82.28 (+0.53), GERN: 2.73 (+0.04), AVEO: 0.91 (-0.02), ICPT: 146.82 (-1.49), AGIO: 36.74 (-0.10), NVS: 78.27 (-0.50)
(0)
(0)Scroll down for more posts ▼